摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-Iod-methylpyridinium | 120879-63-2

中文名称
——
中文别名
——
英文名称
2-Iod-methylpyridinium
英文别名
2-iodo-1-methyl-pyridinium;2-Iodo-1-methylpyridin-1-ium
2-Iod-methylpyridinium化学式
CAS
120879-63-2
化学式
C6H7IN
mdl
——
分子量
220.033
InChiKey
WTBMMENXWDHRKE-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.7
  • 重原子数:
    8
  • 可旋转键数:
    0
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.17
  • 拓扑面积:
    3.9
  • 氢给体数:
    0
  • 氢受体数:
    0

反应信息

  • 作为反应物:
    描述:
    参考文献:
    名称:
    Accelerated hydrolysis of α-halo and α-cyano pyridinium relative to uracil derivatives: a model for ODCase-catalyzed hydrolysis of 6-cyanoUMP
    摘要:
    alpha-Halo and alpha-cyano pyridiniums were found to undergo facile hydrolysis, in contrast to the sluggish reactions of corresponding uracils. The greatly enhanced rates found with pyridinium compounds have indicated a possible source of the rate acceleration seen in the hydrolysis of 6-cyanouridine 5'-monophosphate catalyzed by orotidine 5'-monophosphate decarboxylase. (C) 2011 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.tetlet.2011.05.108
  • 作为产物:
    参考文献:
    名称:
    Exchange Reactions of α-Halogenated Pyridines
    摘要:
    DOI:
    10.1021/jo50001a019
点击查看最新优质反应信息

文献信息

  • Modified Drugs for Use in Liposomal Nanoparticles
    申请人:Cullis Peter
    公开号:US20110165225A1
    公开(公告)日:2011-07-07
    Drag derivatives are provided herein which are suitable for loading into liposomal nanoparticle carriers. In some preferred aspects, the derivatives comprise a poorly water-soluble drag derivatized with a weak-base moiety that facilitates active loading of the drag through a LN transmembrane pH or ion gradient into the aqueous interior of the LN. The weak-base moiety can optionally comprise a lipophilic domain that facilitates active loading of the drag to the inner monolayer of the liposomal membrane. Advantageously, LN formulations of the drag derivatives exhibit improved solubility, reduced toxicity, enhanced efficacy, and/or other benefits relative to the corresponding free drags.
    本文提供了适用于载入脂质体纳米粒子载体的拖曳导数。在某些优选方面,这些导数包括一种难溶于的拖曳经过弱碱基团衍生化,该弱碱基团促进通过LN跨膜pH或离子梯度将拖曳活性负载到LN的内部。弱碱基团可以选择包括一个亲脂性域,该亲脂性域促进将拖曳活性负载到脂质体膜的内单层。优点是,与相应的自由拖曳相比,拖曳导数的LN配方表现出改善的溶解度、降低的毒性、增强的功效和/或其他益处。
  • NITROGEN-CONTAINING SIX-MEMBERED AROMATIC RING DERIVATIVES AND PHARMACEUTICAL PRODUCTS CONTAINING THE SAME
    申请人:Takemoto Naohiro
    公开号:US20100130739A1
    公开(公告)日:2010-05-27
    Provided is a compound that has the ability to promote axonal outgrowth in combination with the ability to promote angiogenesis and can therefore be used to reduce central nerve injuries such as head injury and spinal cord injury, cerebral infarction, ischemic heart diseases such as myocardial infarction and organic angina, peripheral arterial occlusive diseases such as critical limb ischemia, or after-effects of these diseases. Specifically, the compound is represented by the following formula (I): in which Nx group is preferably a 6-membered aromatic ring containing two nitrogen atoms; R 0 , R 1 and R 2 are each independently a hydrogen atom, an alkyl group, an amino group or the like; E is an oxygen atom or an —NR 8 group (wherein R 8 is an alkyl group or the like); n is an integer of 0 to 5; X and Y are each a connecting bond, a cycloalkyl group, —CO— or the like; and Q is a hydrogen atom or a phenyl group.
    提供的是一种化合物,具有促进轴突生长和促进血管生成的能力,因此可用于减少中枢神经损伤,如头部损伤和脊髓损伤,脑梗死,缺血性心脏病,如心肌梗死和器质性心绞痛,周围动脉闭塞性疾病,如严重肢体缺血或这些疾病的后遗症。具体而言,该化合物由以下公式(I)表示: 其中,Nx基团最好是含有两个氮原子的6元芳香环;R0、R1和R2分别独立地是氢原子、烷基、基或类似物;E是氧原子或—NR8基团(其中,R8是烷基或类似物);n是0到5的整数;X和Y分别是连接键、环烷基、—CO—或类似物;Q是氢原子或苯基。
  • A new process for carbapenem intermediates
    申请人:SHIONOGI SEIYAKU KABUSHIKI KAISHA
    公开号:EP0336143A1
    公开(公告)日:1989-10-11
    A novel intermediate for synthesizing 1β-alkyl-1-carbapenem, i.e., 4β-(1β-alkyl-2-carboxyprop-2-enyl)-azetidin-2-one ( II ), is prepared stereoselectively by treating 4-(leaving group substituted)azetidin-2-one ( I ) with trans-2-(leaving group substituted)methyl-3-alkylacrylic acid ( III ) and a reducing metal. wherein, R1 is hydrogen, alkyl, or substituted alkyl; R2 is optionally substituted alkyl; R3 is hydrogen or a carboxy-protecting group; and R4 and R5 each is a leaving group.
    一种合成 1β-烷基-1-碳青霉烯的新型中间体,即 4β-(1β-烷基-2-羧基丙-2-烯基)-氮杂环丁烷-2-酮 ( II ),是通过将 4-(离去基团取代)氮杂环丁烷-2-酮 ( I )与反式-2-(离去基团取代)甲基-3-烷基丙烯酸 ( III )和还原性属进行立体选择性处理而制备的。 其中,R1 是氢、烷基或取代的烷基; R2 是任选取代的烷基 R3 是氢或羧基保护基团;以及 R4 和 R5 各为离去基团。
  • Studies in the Cyanine Dye Series. XI.<sup>1</sup> The Merocyanines
    作者:L. G. S. Brooker、G. H. Keyes、R. H. Sprague、R. H. VanDyke、E. VanLare、G. VanZandt、F. L. White
    DOI:10.1021/ja01155a095
    日期:1951.11
  • Studies in the Cyanine Dye Series. III. Improvements in the 2'-Cyanine Condensation
    作者:L. G. S. Brooker、G. H. Keyes
    DOI:10.1021/ja01315a050
    日期:1935.12
查看更多

同类化合物

(S)-氨氯地平-d4 (R,S)-可替宁N-氧化物-甲基-d3 (R)-(+)-2,2'',6,6''-四甲氧基-4,4''-双(二苯基膦基)-3,3''-联吡啶(1,5-环辛二烯)铑(I)四氟硼酸盐 (R)-N'-亚硝基尼古丁 (R)-DRF053二盐酸盐 (5E)-5-[(2,5-二甲基-1-吡啶-3-基-吡咯-3-基)亚甲基]-2-亚磺酰基-1,3-噻唑烷-4-酮 (5-溴-3-吡啶基)[4-(1-吡咯烷基)-1-哌啶基]甲酮 (5-氨基-6-氰基-7-甲基[1,2]噻唑并[4,5-b]吡啶-3-甲酰胺) (2S,2'S)-(-)-[N,N'-双(2-吡啶基甲基]-2,2'-联吡咯烷双(乙腈)铁(II)六氟锑酸盐 (2S)-2-[[[9-丙-2-基-6-[(4-吡啶-2-基苯基)甲基氨基]嘌呤-2-基]氨基]丁-1-醇 (2R,2''R)-(+)-[N,N''-双(2-吡啶基甲基)]-2,2''-联吡咯烷四盐酸盐 (1'R,2'S)-尼古丁1,1'-Di-N-氧化物 黄色素-37 麦斯明-D4 麦司明 麝香吡啶 鲁非罗尼 鲁卡他胺 高氯酸N-甲基甲基吡啶正离子 高氯酸,吡啶 高奎宁酸 马来酸溴苯那敏 马来酸氯苯那敏-D6 马来酸左氨氯地平 顺式-双(异硫氰基)(2,2'-联吡啶基-4,4'-二羧基)(4,4'-二-壬基-2'-联吡啶基)钌(II) 顺式-二氯二(4-氯吡啶)铂 顺式-二(2,2'-联吡啶)二氯铬氯化物 顺式-1-(4-甲氧基苄基)-3-羟基-5-(3-吡啶)-2-吡咯烷酮 顺-双(2,2-二吡啶)二氯化钌(II) 水合物 顺-双(2,2'-二吡啶基)二氯化钌(II)二水合物 顺-二氯二(吡啶)铂(II) 顺-二(2,2'-联吡啶)二氯化钌(II)二水合物 韦德伊斯试剂 非那吡啶 非洛地平杂质C 非洛地平 非戈替尼 非布索坦杂质66 非尼拉朵 非尼拉敏 雷索替丁 阿雷地平 阿瑞洛莫 阿扎那韦中间体 阿培利司N-6 阿伐曲波帕杂质40 间硝苯地平 间-硝苯地平 镉,二碘四(4-甲基吡啶)- 锌,二溴二[4-吡啶羧硫代酸(2-吡啶基亚甲基)酰肼]-